Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Muscle Atrophy, Obesity, and Cachexia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACVR2B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Ligand Trap) | ACVR2B ECD-Fc Fusion Protein. HEK293 Expressed, High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. | View ACVR2B Products |
| Gene Delivery | ACVR2B Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell line generation. Native conformation preserved. | View ACVR2B Products |
| Benchmark Ab | Anti-ACVR2B (Sequence of Bimagrumab). Recombinant positive control for blocking assays. Sequence Verified. | View ACVR2B Products |
| Validator | ACVR2B siRNA Set. For knockdown verification and assay specificity confirmation. | View ACVR2B Products |
| Related Target A | ACVR2A (Activin Receptor Type IIA). Synergistic type II activin receptor essential for ligand selectivity counter-screening and dual-blockade strategies. | View ACVR2A Products |
| Related Target B | MSTN (Myostatin). Primary natural ligand for ACVR2B; essential for receptor-ligand blocking assays. | View MSTN Products |
| Related Target C | INHBA (Activin A). High-affinity ligand; essential for selectivity profiling (Myostatin vs Activin A discrimination). | View INHBA Products |
| Related Target D | GDF11. Key negative regulator of muscle regeneration; critical off-target liability control for selective trap design. | View GDF11 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Selectivity & Off-target Safety (BMP9/10 sequestration risk) | ACVR2B ECD-Fc Fusion Protein, HEK293 Expressed, >95% Purity, Endotoxin <1 EU/µg. Sequence Verified for accurate ligand-binding kinetics. |
| Cross-species Preclinical Evaluation (Human / Cyno / Mouse) | Human, Cyno, and Mouse ACVR2B ECD Proteins available; strict sequence verification by mass spec for species epitope fidelity. |
| ACVR2A vs ACVR2B Homolog Cross-Reactivity | ACVR2A and ACVR2B homolog panel proteins strictly verified by mass spec and sequencing. |
| Lack of Specificity Controls | Clinical Benchmark Antibodies (Bimagrumab sequence biosimilar) included for assay standardization and potency reference. |
| False Positives in SMAD Reporter Assays | Validated ACVR2B siRNA included for target-specificity confirmation in Activin-responsive reporter cell models. |
Live ACVR2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACVR2B therapeutics has pivoted sharply toward metabolic disease. Following Eli Lilly's acquisition of Versanis Bio and its anti-ACVR2B antibody bimagrumab, the industry is aggressively exploring combinations with GLP-1 receptor agonists to simultaneously drive fat loss and preserve lean muscle mass. First-generation ligand traps such as ACE-031 established proof-of-mechanism in muscle wasting, but the next wave of R&D is defined by ligand-selective blockade—engineering molecules that neutralize Activin A and GDF11 without disrupting protective BMP9/10 signaling required for vascular homeostasis. As oncology and cachexia indications mature, expect a surge in bispecific and tissue-specific decoy receptor formats entering preclinical development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor (ECD-Fc) | Acceleron / Merck (Legacy ACE-031 pipeline) | Duchenne Muscular Dystrophy, Cachexia | Ligand Selectivity Assay (Need high-purity ACVR2B ECD-Fc and homologous ligand panel BMP9/10) |
| Blocking Monoclonal Antibody | Eli Lilly / Versanis, Novartis, Roche (RG7204/GYM329) | Obesity, HFpEF, sIBM, SMA | Receptor Blocking Assay (Need full-length ACVR2B lentivirus stable cell lines & benchmark antibody) |
| Peptide-Fc Fusion | Biogen, Scholar Rock | Metabolic Disorders | Heterodimer Validation (Need cross-reactive ortholog and counter-screen panels) |
| Bispecific / Fusion Protein | Emerging biotech pipelines | Immunometabolic combination therapies | Heterodimer Validation (Need cross-reactive ortholog and counter-screen panels) |
| Gene Therapy (Ancillary) | Novartis, Sarepta | DMD, SMA | Expression Validation (Need Lentivirus for stable cell line construction) |
Molecular Differentiation & Assay Strategy
To develop a best-in-class ACVR2B therapeutic, researchers must address key differentiation dimensions:
- Ligand Selectivity: Ideal drugs should selectively block Myostatin (MSTN) and Activin A (INHBA) while sparing GDF11 (linked to hematopoiesis and angiogenesis). TarMart provides recombinant MSTN, INHBA, and GDF11 for competition binding assays, plus ACVR2B ECD-Fc for SPR/BLI kinetic analysis.
- Cross-species Reactivity: Preclinical studies require human, cynomolgus, and mouse ACVR2B ECD proteins (available at >95% purity) for cross-reactivity validation via ELISA/flow cytometry.
- Paralog Selectivity (ACVR2A vs ACVR2B): Counter-screening with ACVR2A homolog panel and lentivirus-based cell lines ensures selective targeting.
- Developability: HEK293 expression ensures native glycosylation; high purity (>95%) and low endotoxin (<1 EU/µg) minimize non-specific binding in sensitive cell-based assays.
Recommended Assay Workflow:
- Primary screening: ACVR2B ECD-Fc ELISA to identify MSTN-blocking antibodies.
- Selectivity validation: Counter-screen against ACVR2A homolog.
- Functional validation: ACVR2B-lentivirus transduced C2C12 cells for p-SMAD2/3 inhibition.
- Mechanism confirmation: ACVR2B siRNA knockdown to confirm on-target effects.